Monitor the upcoming Q1 2026 10-Q for actual financial results and cash position. The preliminary cash estimate from this analyst day presentation is unlikely to drive stock movement without additional context.
Price Chart
Executive Summary
Perspective Therapeutics filed an 8-K reporting that it posted a presentation with estimated cash, cash equivalents, and short-term investments as of March 31, 2026, which are preliminary and unaudited. No actual financial results or guidance were disclosed, making this a routine update with limited material information.
Key Facts
- Filing 8-K with Items 2.02 and 8.01, related to an analyst event presentation posted on May 4, 2026.
- Presentation contains estimated cash, cash equivalents, and short-term investments as of March 31, 2026, which are preliminary and unaudited.
- No actual Q1 2026 revenue, EPS, or other financial results are reported in this filing.
- Company had ~$145M cash at FY2025 end and completed a ~$164M equity offering in February 2026.
Financial Impact
No financial figures are disclosed in the filing—only preliminary estimated cash data.
Risk Factors
- Preliminary data may differ materially from final reported results.
- No new operational or clinical milestones were announced.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204161 |
| Document: catx-ex99_1.htm | 0001193125-26-204161 |
| Document: 0001193125-26-204161-index-headers.html | 0001193125-26-204161 |
| Document: 0001193125-26-204161-index.html | 0001193125-26-204161 |
| Document: 0001193125-26-204161.txt | 0001193125-26-204161 |
| 8-K Data (Synthetic) | 0001193125-26-204161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers